Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 663-675

  Zhai, Z J ^a   Li, H W ^a   Liu, G W ^b   Qu, X H ^a   Tian, B ^a   Yan, W ^c   Lin, Z ^d,e   Tang, T T ^a   Qin, A ^a,e   Dai, K R ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c Wendeng Zhenggu Hospital of Shandong Province   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

andrographolide; ERK; NF B; osteoclast; osteolysis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANDROGRAPHOLIDE; CALCITONIN RECEPTOR; CATHEPSIN K; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANDROGRAPHIS PANICULATA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FEMUR; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANDROGRAPHOLIDE; ERK; NF-ΚB; OSTEOCLAST; OSTEOLYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DITERPENES; DOWN-REGULATION; FEMALE; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; RANK LIGAND; RECOMBINANT PROTEINS;

EID: 84892422316     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12463     Document Type: Article

References (62)

1. Abu-Ghefreh AA, Canatan H, Ezeamuzie CI, (2009). In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol 9: 313-318.
2. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, et al. (2006). A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 116: 1525-1534.
3. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. (2005). Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202: 1261-1269.
4. Bao Z, Guan S, Cheng C, Wu S, Wong SH, Kemeny DM, et al. (2009). A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-κB pathway. Am J Respir Crit Care Med 179: 657-665.
5. Boyle WJ, Simonet WS, Lacey DL, (2003). Osteoclast differentiation and activation. Nature 423: 337-342.
6. Cappuzzo KA, Delafuente JC, (2004). Teriparatide for severe osteoporosis. Ann Pharmacother 38: 294-302.
7. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR, (1995). Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9-16.
8. Çetinkaya MB, Kökçü A, Yanik FF, Başoǧlu T, Malatyalioglu E, Alper T, (2002). Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women. J Bone Miner Metab 20: 44-48.
9. Chen JH, Hsiao G, Lee AR, Wu CC, Yen MH, (2004). Andrographolide suppresses endothelial cell apoptosis via activation of phosphatidyl inositol-3-kinase/Akt pathway. Biochem Pharmacol 67: 1337-1345.
10. Colditz GA, (1997). Hormone replacement therapy increases the risk of breast cancer. Ann N Y Acad Sci 833: 129-136.
11. Feng X, (2005). RANKing intracellular signaling in osteoclasts. IUBMB Life 57: 389-395.
12. Hidalgo MA, Romero A, Figueroa J, Cortés P, Concha II, Hancke JL, et al. (2005). Andrographolide interferes with binding of nuclear factor-κB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 144: 680-686.
13. Hiligsmann M, Boonen A, Dirksen CD, Sedrine WB, Reginster J-Y, (2013). Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res 13: 19-28.
14. Huang Q-Q, Pope RM, (2009). The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 11: 357-364.
15. Josse R, Khan A, Ngui D, Shapiro M, (2013). Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Curr Med Res Opin 29: 205-216.
16. Keating SE, Maloney GM, Moran EM, Bowie AG, (2007). IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem 282: 33435-33443.
17. Khor EC, Abel T, Tickner J, Chim SM, Wang C, Cheng T, et al. (2013). Loss of protein kinase C-δ protects against LPS-induced osteolysis owing to an intrinsic defect in osteoclastic bone resorption. PLoS ONE 8: e70815.
18. Khosla S, (2001). Minireview: the opg/rankl/rank system. Endocrinology 142: 5050-5055.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kim BG, Kwak HB, Choi E-Y, Kim HS, Kim MH, Kim SH, et al. (2010). Amorphigenin inhibits osteoclast differentiation by suppressing c-Fos and nuclear factor of activated T cells. Anat Cell Biol 43: 310-316.
21. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. (2000). Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286.
22. Kogawa M, Hisatake K, Atkins GJ, Findlay DM, Enoki Y, Sato T, et al. (2013). The paired-box domain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses RANKL-induced osteoclast differentiation. J Biol Chem 288: 31299-31312.
23. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O, (2001). Tumor necrosis factor-α cooperates with receptor activator of nuclear factor κB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 28: 474-483.
24. Kong YY, Boyle WJ, Penninger JM, (2000). Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 21: 495-502.
25. Kousteni S, Bellido T, Plotkin L, O'Brien C, Bodenner D, Han L, et al. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730.
26. Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, et al. (2010). Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46: 724-731.
27. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL, (2000). TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488.
28. Lee J-M, Park H, Noh ALSM, Kang J-H, Chen L, Zheng T, et al. (2012). 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1. J Immunol 189: 5284-5292.
29. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, et al. (2002). Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22: 992-1000.
31. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. (2007). Estrogen prevents bone loss via estrogen receptor [alpha] and induction of fas ligand in osteoclasts. Cell 130: 811-823.
32. Negi AS, Kumar J, Luqman S, Shanker K, Gupta M, Khanuja S, (2008). Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 28: 746-772.
33. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J-I, Cao Z, Matsumoto K, (1999). The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
34. Novack DV, (2010). Role of NF-κB in the skeleton. Cell Res 21: 169-182.
35. Qin A, Cheng TS, Lin Z, Pavlos NJ, Jiang Q, Xu J, et al. (2011). Versatile roles of V-ATPases accessory subunit Ac45 in osteoclast formation and function. PLoS ONE 6: e27155.
36. Qin A, Cheng T, Pavlos N, Lin Z, Dai K, Zheng M, (2012a). V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol 7: Issue 4, e34132, 1-11.
37. Qin A, Cheng TS, Lin Z, Cao L, Chim SM, Pavlos NJ, et al. (2012b). Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS ONE 7: e34132.
38. Reddy VLN, Reddy SM, Ravikanth V, Krishnaiah P, Goud TV, Rao T, et al. (2005). A new bis-andrographolide ether from Andrographis paniculata nees and evaluation of anti-HIV activity. Nat Prod Res 19: 223-230.
39. Rizzoli R, (2005). A new treatment for post-menopausal osteoporosis: strontium ranelate. J Endocrinol Invest 28 (8 Suppl): 50-57.
40. Rodan GA, Martin TJ, (2000). Therapeutic approaches to bone diseases. Science 289: 1508-1514.
41. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick M, et al. (2002). Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
42. Shen YC, Chen CF, Chiou WF, (2002). Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol 135: 399-406.
43. Soysa N, Alles N, (2009). NF-κB functions in osteoclasts. Biochem Biophys Res Commun 378: 1-5.
44. Stevenson DA, Schwarz E, Carey JC, Viskochil DH, Hanson H, Bauer S, et al. (2011). Bone resorption in syndromes of the Ras/MAPK pathway. Clin Genet 80: 566-573.
45. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ, (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357.
46. Takaesu G, Ninomiya-Tsuji J, Kishida S, Li X, Stark GR, Matsumoto K, (2001). Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol 21: 2475-2484.
47. Takahashi N, Udagawa N, Tanaka S, Suda T, (2003). Generating murine osteoclasts from bone marrow. Methods Mol Med 80: 129-144.
48. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
49. Teitelbaum SL, Ross FP, (2003). Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649.
50. Verron E, Bouler J, (2013). Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? Drug Discov Today 116: 115-120.
51. Wang C, Steer JH, Joyce DA, Yip KHM, Zheng MH, Xu J, (2003). 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-κB activation. J Bone Miner Res 18: 2159-2168.
52. Wang YJ, Wang JT, Fan QX, Geng JG, (2007). Andrographolide inhibits NF-κB activation and attenuates neointimal hyperplasia in arterial restenosis. Cell Res 17: 933-941.
53. Wedemeyer C, Xu J, Neuerburg C, Landgraeber S, Malyar NM, von Knoch F, et al. (2007). Particle-induced osteolysis in three-dimensional micro-computed tomography. Calcif Tissue Int 81: 394-402.
54. Weitzmann MN, Pacifici R, (2006). Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 1068: 256-274.
55. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X, et al. (2004). Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 173: 4207-4217.
56. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. (2007). NF-kB p50 and p52 regulate RANKL and TNF-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282: 18245-18253.
57. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, et al. (2002). Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418: 443-447.
58. Zhang H, Wu C, Matesic LE, Li X, Wang Z, Boyce BF, et al. (2013). Ubiquitin E3 ligase itch negatively regulates osteoclast formation by promoting deubiquitination of tumor necrosis factor (TNF) receptor-associated factor 6. J Biol Chem 288: 22359-22368.
59. Zhao J, Yang G, Liu H, Wang D, Song X, Chen Y, (2002). Determination of andrographolide, deoxyandrographolide and neoandrographolide in the Chinese herb Andrographis paniculata by micellar electrokinetic capillary chromatography. Phytochem Anal 13: 222-227.
60. Zhao Q, Wang X, Liu Y, He A, Jia R, (2010). NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 42: 576-579.
61. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z, (2001). Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83: 70-83.
62. Zou W, Izawa T, Zhu T, Chappel J, Otero K, Monkley SJ, et al. (2013). Talin1 and Rap1 are critical for osteoclast function. Mol Cell Biol 33: 830-844.